Development of a 89Zr radiolabeled anti-CD33 antibody for PET imaging of Acute Myeloid Leukemia

被引：0
|
作者：
Buckway, Brandon [1 ]
Burrell, Lance [2 ]
Shami, Paul [2 ]
Kosak, Ken [2 ]
Lum, David [2 ]
Yap, Jeffrey [1 ]
机构：
[1] Huntsman Canc Inst, Ctr Quantitat Canc Imaging, Salt Lake City, UT USA
[2] Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1053
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Immuno-PET imaging of 89Zr labeled anti-PD-L1domain antibody
    Li, Dan
    Cheng, Siyuan
    Zhu, Xiao-Hua
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [22] Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
    Stasi, Roberto
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (04) : 527 - 540
  • [23] The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
    Egan, Pamela C.
    Reagan, John L.
    ONCOTARGETS AND THERAPY, 2018, 11 : 8265 - 8272
  • [24] Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy
    Niu, Fan
    Yan, Jin
    Ma, Bohan
    Li, Shichao
    Shao, Yongping
    He, Pengcheng
    Zhang, Wanggang
    He, Wangxiao
    Ma, Peter X.
    Lu, Wuyuan
    BIOMATERIALS, 2018, 167 : 132 - 142
  • [25] Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
    Sievers, EL
    Appelbaum, FR
    Spielberger, RT
    Forman, SJ
    Flowers, D
    Smith, FO
    Shannon-Dorcy, K
    Berger, MS
    Bernstein, ID
    BLOOD, 1999, 93 (11) : 3678 - 3684
  • [26] ANTI-CD33 ACTINIUM-225 TARGETED RADIOIMMUNOTHERAPY ENHANCES THE BIOLOGIC ACTIVITY OF ANTI-CD47 ANTIBODY IMMUNOTHERAPY IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA
    Pachhal, Sagarika
    Greer, Emily
    Hwang, Jesse
    Liang, Qing
    Chen, Mary
    Geoghegan, Eileen
    Kotanides, Helen
    Ludwig, Dale
    Beckford, Denis
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A620 - A620
  • [27] Bispecific anti-CD33 x anti-CD64 antibody augments the effects of Ara-C and INF-γ on acute myeloid leukemia cells.
    Balaian, L
    Ball, ED
    BLOOD, 2000, 96 (11) : 115A - 115A
  • [28] MODELING AND DOSIMETRY OF MONOCLONAL-ANTIBODY M195 (ANTI-CD33) IN ACUTE MYELOGENOUS LEUKEMIA
    SGOUROS, G
    GRAHAM, MC
    DIVGI, CR
    LARSON, SM
    SCHEINBERG, DA
    JOURNAL OF NUCLEAR MEDICINE, 1993, 34 (03) : 422 - 430
  • [29] Immuno-PET Imaging of Atherosclerotic Plaques with [89Zr]Zr-Anti-CD40 mAb-Proof of Concept
    Poels, Kikkie
    Schreurs, Maxime
    Jansen, Matthijs
    Vugts, Danielle J.
    Seijkens, Tom T. P.
    van Dongen, Guus A. M. S.
    Lutgens, Esther
    Beaino, Wissam
    BIOLOGY-BASEL, 2022, 11 (03):
  • [30] Autologous bone marrow transplant (BMT) purged with anti-CD33 immunotoxin for patients with acute myeloid leukemia (AML).
    Lavoie, J
    Bélanger, R
    Robertson, MJ
    Stone, R
    Perreault, C
    Kassis, J
    Busque, L
    Soiffer, RJ
    Ritz, J
    Roy, DC
    BLOOD, 1998, 92 (10) : 323A - 323A
12345